Background/Objectives
AMD, atrophy
SECONDARY, AGE-RELATED MACULAR DEGENERATION, ATROPHY
To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course.